



Determinazione del Responsabile Ufficio Formazione n° 301 del 7 APR. 2015

Oggetto: Aggiornamento obbligatorio senza oneri, Dirigente Medico, Dott. De Giorgi Franco.

Publicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal ~~6~~ 7 APR. 2015 per 15 giorni consecutivi e posta a disposizione per la consultazione.

Il Responsabile Ufficio Formazione

- Visto** il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;
- Viste** le Leggi Regionali n. 10/2006 e n. 05/2007;
- Vista** la Deliberazione n. 263 del 04.03.2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le Determinazioni;
- Vista** la comunicazione Prot. n° 7168 del 25.03.2015 con la quale la Ditta N.G.C. Medical S.r.L. si è resa disponibile ad invitare un Medico della S.C. di Radiologia al Congresso: "Charing Cross" che si terrà a Londra dal 28.04.2015 al 01.05.2015;
- Considerato** che il Direttore del Dipartimento Servizi ha autorizzato a partecipare al suddetto Congresso il Dott. De Giorgi Franco;
- Atteso** che il Responsabile dell'Ufficio Formazione ha espresso parere favorevole in merito;
- Ritenuto** di dover autorizzare la partecipazione del Dott. De Giorgi Franco al Congresso: " Charing Cross" che si terrà a Londra dal 28.04.2015 al 01.05.2015; di dover prendere atto che le spese di partecipazione saranno totalmente a carico della Ditta N.G.C. Medical S.r.L.


DETERMINA

Per i motivi esposti in premessa:

1. Autorizzare la partecipazione del Dott. De Giorgi Franco al Congresso: " Charing Cross" che si terrà a Londra dal 28.04.2015 al 01.05.2015.
2. Dare atto che le spese di partecipazione saranno totalmente a carico della Ditta N.G.C. Medical S.r.L.
3. Trasmettere la presente determinazione al Direttore della S.C. del Personale per gli adempimenti normativi di competenza.

Il Responsabile dell'Ufficio Formazione
Dott. Andrea Corrias

Andrea Corrias
AZIENDA OSPEDALIERA G. BROTZU
UFFICIO FORMAZIONE



AO BROTZU

PG/2015/ 0007168 del 25/03/2015 ore 10,22

Mittente NGC MEDICAL

Assegnatario Ufficio Formazione



Spett.le
A.O. Brotzu
P.le A. Ricchi, 1
09100 Cagliari CA

Novedrate, 20 marzo 2015

Alla c.a.: - Direzione Generale
- Direzione Sanitaria

OGGETTO: Congresso Charing Cross – Londra, 28 aprile/1 maggio 2015

Abbiamo il piacere di informarVi che, nell'ambito del contratto di service, saremmo lieti di supportare la partecipazione di due medici del S.S.D. Radiologia e Neuroradiologia Interventistica Vascolare.

Il congresso in oggetto si terrà presso l'Olympia Grand dal 28 aprile all'1 maggio e verranno trattati aspetti clinici e medici di importante interesse per la comunità medica, nonché per il migliore e più corretto impiego terapeutico della tecnologia medica.

N.G.C. Medical ritiene che il sostegno a favore di eventi formativi specifici costituisca parte del proprio contributo volto al miglioramento della qualità di vita dei pazienti.

Il programma scientifico è consultabile e scaricabile dal sito www.cxvasc.com/cxsymposium.

N.G.C. Medical sarà disponibile a sostenere le seguenti spese necessarie alla partecipazione:

- Iscrizione;
- Spese viaggio: biglietto aereo;
- Pernottamento: 4 notti;
- Pasti: per la durata dell' evento.

Si precisa che la presente comunicazione viene fatta per garantire la piena trasparenza con riferimento alla sponsorizzazione di iscrizioni a congressi, in ottemperanza al proprio codice etico. N.G.C. Medical, infatti, è una società che opera nel settore biomedicale e pertanto non è soggetta alle autorizzazioni ed in ogni caso agli obblighi di legge previsti nel decreto legislativo n. 541 del 30.12.1992 specifico per le aziende che commercializzano medicinali o specialità farmaceutiche.

Restiamo in attesa di Vostro cortese riscontro alla presente e dei nominativi, al fine di organizzare i dettagli della partecipazione.

Cordiali saluti.

N.G.C. MEDICAL S.r.l.

Il Procuratore
Dr. Paolo Cremascoli

N.G.C. Medical S.r.l.

Società a Socio Unico

22060 Novedrate (CO) – Strada Prov. Novedratese 35

phone +39.031.7941.11 – fax +39.031.792130

www.ngc.it – e-mail ngc@ngc.it – capitale sociale € 4.000.000,00 i.v.

partita iva 02196770131 – R.E.A. CO-234052

codice fiscale e n. registrazione Registro Imprese di Como 09831040150

Il Prof. Dr. Grazia Bitti
Paolo Cremascoli

AZIENDA OSPEDALIERA "G. BROTZU"
S.C. di RADIOLOGIA
Direttore: Dott. Grazia Bitti

AZIENDA OSPEDALIERA "G. BROTZU"
DIREZIONE SERVIZI
Direttore: Dott. PAOLO BACCHIDDI

AZIENDA OSPEDALIERA "G. BROTZU"
UFFICIO FORMAZIONE

Le Giorgi ^{FRANCO} + Co ^{SIMONA} REAIME NGC



[CX Symposium](#) [Programme](#) [Sponsored Events](#) [Register](#) [Exhibitors](#) [2014](#) [Archive](#) [Shop](#)

2015 Main Programme

Quic



Registration is now open, [click here to register](#)

[Tuesday](#) | [Wednesday](#) | [Thursday](#) | [Friday](#)

Tuesday 28 April 2015 – Main Programme PERIPHERAL ARTERIAL CONTROVERSIES

Basic principles and imaging

Chairman: Cliff Shearman. *Southampton, United Kingdom*

Moderator: Ian Franklin. *Imperial College, London, United Kingdom*

[Click here to read about the highlights of the Peripheral Arterial Controversies 2015.](#)

08:00-08:10

Essential management for every patient with intermittent claudication before consideration of intervention

Frans Moll. *Utrecht, Netherlands*

08:10-08:15

Discussion

08:15-08:25

3D lower limb perfusion during critical limb ischaemia

Andrew Holden. *Auckland, New Zealand*

08:25-08:30

Discussion

08:30-08:40

Contrast reduction angiography for peripheral arterial disease

Martin Malina, *Malmö, Sweden*

08:40-08:45

Discussion

08:45-08:55

Debate: IVUS is worth the cost for peripheral arterial disease

For the motion: Fabrizio Fanelli, *Rome, Italy*

Against the motion: Patrick Peeters, *Bonheiden, Belgium*

08:55-09:00

Discussion and vote

09:00-09:10

There is no advantage using heparin with intra-arterial thrombolysis

Anders Wanhainen, *Uppsala, Sweden*

09:10-09:15

Discussion

09:15-09:25

Definition of success of superficial femoral artery interventions

Peter Schneider, *Honolulu, United States*

09:25-09:30

Discussion

Iliac reconstruction controversies

09:30-09:40

Early clinical outcomes with a new flexible endoluminal stent graft for iliac artery disease

Andrew Holden, *Auckland, New Zealand*

09:40-09:45

Discussion

Superficial femoral artery (SFA) controversies

09:45-09:55

Debate: Endovascular beats open surgery for TASC C & D SFA lesions irrespective of lesion location

For the motion: Thomas Zeller, *Bad Krozingen, Germany*

Against the motion: Malcolm Simms, *Birmingham, United Kingdom*

09:55-10:00

Discussion and vote

COFFEE - Refreshments will also be served in the Main Auditorium

Preference to use a stent in the superficial femoral artery

With an unrestricted educational grant from Abbott Vascular

Chairman: Michael Jaff, *Boston, United States*

10:00-10:03

Coffee & snacks

10:03-10:09

My stent rate for the superficial femoral artery rate is increasing

Andrew Holden, *Auckland, New Zealand*

10:09-10:12

Discussion

10:12-10:18

The European clinical experience of SUPERA

Iris Baumgartner, *Bern, Switzerland*

10:18-10:21

Discussion

10:21-10:28

Chairman's case discussion with audience interaction

Michael Jaff, *Boston, United States*

The "Leaving nothing behind" controversy

Chairman: Roger Greenhalgh, *Imperial College, London, United Kingdom*

Moderator: Iris Baumgartner, *Bern, Switzerland*

10:30-10:37

Biosorbable stent – 480° Biomedical

Andrew Holden, *Auckland, New Zealand*

10:37-10:44

DEFINITIVE AR atherectomy and drug-coated balloons at one year

Thomas Zellér, *Bad Krozingen, Germany*

10:44-10:51

EverFlex – Seven-year data

Giovanni Torsello, *Münster, Germany*

10:51-10:58

The FREEDOM trial – a one-handed delivery system for same-day discharge

Yann Goueffic, *Nantes, France*

10:58-11:05

Shockwave Lithoplasty for calcified artery

Andrew Holden, *Auckland, New Zealand*

11:05-11:22

Panel discussion

Drug-coated balloon update

11:22-11:30

Current status of drug-eluting balloon use in the superficial femoral artery

Fabrizio Fanelli, *Rome, Italy*

11:30-11:38

Update on Lutonix drug-eluting balloon

Dierk Scheinert, *Leipzig, Germany*

11:38-11:46

ILLUMENATE study – 24-month results

Stephan Duda, *Berlin, Germany*

11:46-11:54

IN.PACT SFA update

Gunnar Tepe, *Rosenheim, Germany*

11:54-12:02

Cost-effectiveness of drug-coated balloons

Michael Jaff, *Boston, United States*

12:02-12:10

Methodology differences

Thomas Zeller, *Bad Krozingen, Germany*

12:10-12:30

Panel discussion on drug-coated balloons and algorithm of care

LUNCH - Food will also be served in the Main Auditorium

Industry sponsored satellite

12:30-13:00 [Click here](#)

Industry sponsored satellite

13:00-13:30 [Click here](#)

Increasing lesion length options and various stent controversies

Chairman: Roger Greenhalgh, *Imperial College, London, United Kingdom*

Moderator: Andrew Holden, *Auckland, New Zealand*

13:30-13:38

Paradigms and importance of lesion length and type

William Gray, *New York, United States*

13:38-13:41

Discussion

13:41-13:49

Lower profile robotic catheter use for internal prosthetic bypasses

Alan Lumsden, *Houston, United States*

13:49-13:52

Discussion

13:52-14:00

Zilver PTX – final results at five years

Michael Dake, *Stanford, United States*

14:00-14:03

Discussion

14:03-14:11

The value of drug elution on a new bare metal stent – SuperNova to Majestic

Richard Powell, *Lebanon, United States*

14:11-14:14

Discussion

14:14-14:22

Lesion up to 100mm

Konstantinos Katsanos, *London, United Kingdom*

14:22-14:25

Discussion

14:25-14:33

The SUPERA stent for superficial femoral artery lesions even with calcification

Firas Mussa, *New York, United States*

14:33-14:36

Discussion

14:36-14:44

The value of Smart Flex for femoropopliteal disease

Peter Goverde, *Antwerp, Belgium*

14:44-14:47

Discussion

14:47-14:55

Stent graft and double stent graft for very long lesions in the SFA

Daniele Savio, *Turin, Italy*

14:55-14:58

Discussion

14:58-15:06

Long-term results of laser and drug-eluting balloon for in-stent restenosis

Jos van den Berg, *Lugano, Switzerland*

15:06-15:09

Discussion

15:09-15:30

Panel discussion on stent usage and longer lesions

TEA - Refreshments will also be served in the Main Auditorium

Industry sponsored satellite

15:30-16:00 [Click here](#)

Open surgical controversy

Chairman: Paul Blair, *Belfast, United Kingdom*

Moderator: Cliff Shearman, *Southampton, United Kingdom*

16:00-16:10

Debate: Heparin bonding benefits superficial femoral artery PTFE bypass results

For the motion: Russell Samson, *Sarasota, United States*

Against the motion: Jonathan Beard, *Sheffield, United Kingdom*

16:10-16:20

Discussion and vote

Popliteal debate

16:20-16:30

Debate: Popliteal aneurysm should be treated by endovascular means

For the motion: Michele Antonello, *Padua, Italy*

Against the motion: Martin Björck, *Uppsala, Sweden*

16:30-16:40

Discussion and vote

Below the knee

Chairman: Frans Moll, *Utrecht, Netherlands*

Moderator: Michael Edmonds, *London, United Kingdom*

16:40-16:48

Definition of critical limb ischaemia

Jim Reekers, *Amsterdam, Netherlands*

16:48-16:56

Appraisal of rotational atherectomy in calcified infrapopliteal lesions

Fabrizio Fanelli, *Rome, Italy*

16:56-17:04

The angiosome concept is convincing

Maarit Venermo, *Helsinki, Finland*

17:04-17:12

Current status of below-the-knee interventions

Thomas Zeller, *Bad Krozingen, Germany*

17:12-17:20

Influence of steroid on chronic limb ischaemia – similar in severity to the nephropathic foot

Iris Baumgartner, *Bern, Switzerland*

17:20-17:28

PADI trial one-year results – drug-eluting stents vs. PTA

Hans van Overhagen, *Den Haag, Netherlands*

17:28-17:36

Lower restenosis of long below-the-knee lesions at six months with everolimus-eluting stent vs. paclitaxel-coated balloon

Konstantinos Katsanos, *London, United Kingdom*

17:36-18:00

Panel discussion on effectiveness of treatment options

Additional Peripheral Arterial activities

GX Abstracts – Peripheral

Tuesday 28 April and Wednesday 29 April - [Click here](#)

LINC@CX

Wednesday 29 April - [Click here](#)

NEW CX Live Peripheral Arterial Cases

Wednesday 29 April - [Click here](#)

CX ilegx Collaboration Day

Thursday 30 April - [Click here](#)

Wednesday 29 April 2015 – Main Programme

ABDOMINAL AORTIC CONTROVERSIES

Epidemiology, indications and medical management

Chairman: Andrew Holden, *Auckland, New Zealand*

Moderator: Giovanni Torsello, *Münster, Germany*

[Click here to read about the highlights of the Abdominal Aortic Controversies 2015.](#)

08:00-08:08

Life style other than smoking and the risk for abdominal aortic aneurysm

Frank Lederle, *Minneapolis, United States*

08:08-08:11

Discussion

08:11-08:19

Factors associated with abdominal aortic aneurysm expansion and rupture

Janet Powell, *Imperial College, London, United Kingdom*

08:19-08:22

Discussion

08:22-08:30

Threshold for elective intervention

Kevin Mani, *Uppsala, Sweden*

08:30-08:33

Discussion

08:33-08:41

Endovascular indications for embolising aortic lesions

Michel Makaroun, *Pittsburgh, United States*

08:41-08:44

Discussion

Ruptured abdominal aortic aneurysm

08:44-08:52

Intraoperative CT in EVAR is also helpful in ruptured cases

Dittmar Böckler, *Heidelberg, Germany*

08:52-08:55

Discussion

08:55-09:03

IMPROVE trial – net benefit results at 12 months

Janet Powell, *London, United Kingdom*

09:03-09:06

Discussion

09:06-09:14

Twelve-month outcomes – IPD 3 trial

Ron Balm, *Amsterdam, Netherlands*

09:14-09:17

Discussion

09:17-09:25

Responsibilities of disciplines after ruptured abdominal aortic aneurysm by day and night

Jan de Waele, *Ghent, Belgium*

09:25-09:28

Discussion

09:28-09:38

Debate: Too many patients with rAAA are denied intervention

For the motion: Matt Thompson, *London, United Kingdom*

Against the motion: Peter Lamont, *Bristol, United Kingdom*

09:38-09:43

Discussion and vote

09:43-10:00

Panel discussion

COFFEE - Refreshments will also be served in the Main Auditorium

Industry sponsored satellite

10:00-10:30 [Click here](#)

Procedures for infra-renal abdominal aortic neck

Chairman: Roger Greenhalgh, *Imperial College, London, United Kingdom*

Moderator: Frans Moll, *Utrecht, Netherlands*

10:30-10:38

Morphology findings from the IMPROVE trial

Robert Hinchliffe, *London, United Kingdom*

10:38-10:41

Discussion

10:41-10:49

EVAR alone is first choice for aortic neck <15mm

Hence Verhagen, *Rotterdam, Netherlands*

10:49-10:52

Discussion

10:52-11:00

Open repair is best more often than not

Juerg Schmidli, *Bern, Switzerland*

11:00-11:03

Discussion

11:03-11:11

Choice of device for short neck and appraisal of FEVAR

Timothy Resch, *Malmö, Sweden*

11:11-11:14

Discussion

11:14-11:22

The place for parallel grafts

Mario Lachat, *Zurich, Switzerland*

11:22-11:25

Discussion

11:25-11:33

The influence of polymer filled technology on choices and also if a parallel graft is used

Matt Thompson, *London, United Kingdom*

11:33-11:36

Discussion

11:36-11:44

Potential benefit from robotic navigation with 3D imaging for complex anatomy and endovascular procedures

Alan Lumsden, *Houston, United States*

11:44-11:47

Discussion

11:47-11:55

The value of polymer-filled sealing ring technology for abdominal aortic aneurysm

David Minion, *Lexington, United States*

11:55-11:58

Discussion

11:58-12:08

Debate: EVAR is not sensible for any abdominal aortic aneurysm with a neck length less than 10mm

For the motion: Stephen Cheng, *Hong Kong*

Against the motion: Jan Blankensteijn, *Amsterdam, Netherlands*

12:08-12:13

Discussion and vote

12:13-12:30

Panel discussion on short infrarenal aortic neck

First discussant from the floor: Rao Vallabhaneni, *Liverpool, United Kingdom*

LUNCH - Food will also be served in the Main Auditorium

Industry sponsored satellite

12:30-13:00 [Click here](#)

Results of INCRAFT at three years

With an unrestricted educational grant from Cordis

Chairman: Eric Ducasse, *Bordeaux, France*

13:00-13:02

Coffee & snacks

13:02-13:10

The INNOVATION study at three years: Accuracy of placement achieved

Giovanni Pratesi, *Florence, Italy*

13:10-13:15

Discussion

13:15-13:23

High expectations of cost-effectiveness

Arne Schwandt, *Münster, Germany*

13:23-13:28

Discussion

Mini-symposium: Radiation exposure to operator and patient

Chairman: Frans Moll, *Utrecht, Netherlands*

Moderator: Janet Powell, *Imperial College, London, United Kingdom*

13:30-13:38

Radiation levels for mobile, fixed and clarity fixed C-arm fluoroscopy

Joost van Herwaarden, *Utrecht, Netherlands*

13:38-13:40

Discussion

13:40-13:48

Reduction of radiation to all involved in endovascular procedures

Lindsay Machan, *Vancouver, Canada*

13:48-13:50

Discussion

13:50-13:58

Reduction of radiation to the operator

Barry Katzen, *Miami, United States*

13:58-14:00

Discussion

14:00-14:08

Doing more with less – dose optimised imaging protocols for complex endovascular procedures

Eric Verhoeven, *Nuremberg, Germany*

14:08-14:10

Discussion

14:10-14:19

Panel discussion

Technical approaches for elective aneurysm repair

14:19-14:29

Launch: Six-month results of a new iliac branch endoprosthesis

Darren Schneider, *New York, United States*

14:29-14:31

Discussion

14:31-14:39

Branched iliac device prevents gluteal claudication in aorto-iliac aneurysms

Lars Lonn, *Copenhagen, Denmark*

14:39-14:41

Discussion

14:41-14:49

The treatment of aortic graft infection by a technique using femoral vein and fascial strengthening

Maarit Venermo, *Helsinki, Finland*

14:49-14:51

Discussion

14:51-14:59

Non-radical management of infected aortic grafts

Martin Malina, *Malmö, Sweden*

14:59-15:01

Discussion

15:01-15:09

A new repositionable and conformable endograft system for expected improved EVAR device

Robert Rhee, *New York, United States*

15:09-15:11

Discussion

15:11-15:19

Elective AAA repair in octo- and nonagenarians

Kevin Mani, *Uppsala, Sweden*

15:19-15:21

Discussion

15:21-15:30 **Panel discussion**

TEA - Refreshments will also be served in the Main Auditorium

Changing the standard of care with EndoVascular Aneurysm Sealing (EVAS)

With an unrestricted educational grant from Endologix

Chairman: Andrew Holden, *Auckland, New Zealand*

15:30-15:38

EVAS patient selection and case planning

Jan Heyligers, *Tilburg, Netherlands*

15:38-15:43

Discussion

15:43-15:51

Radiologic and duplex protocols and appearances for EVAS

Andrew Winterbottom, *Cambridge, United Kingdom*

15:51-15:56

Discussion

15:56-16:04

EVAS for acute AAA: How to do it and early results

Michel Reijnen, *Arnhem, Netherlands*

16:04-16:09

Discussion

16:09-16:17

Building evidence to support EVAS as the next gold standard

Matt Thompson, *London, United Kingdom*

16:17-16:22

Discussion

16:22-16:27

Panel Discussion

Follow-up

Chairman: Roger Greenhalgh, *Imperial College, London, United Kingdom*

Moderator: Sebastian Debus, *Hamburg, Germany*

16:30-16:40

Debate: At least one follow-up visit with imaging, ultrasound or CT each five years is required after EVAR

For the motion: Janet Powell, *Imperial College, London, United Kingdom*

Against the motion: Michael Wyatt, *Newcastle-upon-Tyne, United Kingdom*

16:40-16:45

Discussion and vote

16:45-16:53

EVAR – surveillance protocol 20 years after EVAR introduction

Fabio Verzini, *Perugia, Italy*

16:53-16:55

Discussion

16:55-17:03

Performance of new generation endografts in more than 900 patients with different anatomic scenarios: what we have learned

Theodosios Bisdas, *Münster, Germany*

17:03-17:05

Discussion

17:05-17:13

The impact of EVAS on secondary interventions compared with EVAR

Andrew Holden, *Auckland, New Zealand*

17:13-17:15

Discussion

17:15-17:23

Endoleak is associated with sac growth but not mortality (OVER trial)

Frank Lederle, *Minneapolis, United States*

17:23-17:25

Discussion

17:25-17:35

Panel discussion

Mini-symposium: Management of type I endoleaks

17:35-17:45

Debate: Liquid embolic products and glues are indicated for type I endoleaks

For the motion: Robert Morgan, *London, United Kingdom*

Against the motion: Fabrizio Fanelli, *Rome, Italy*

17:45-17:50

Discussion and vote

17:50-17:58

Extension fenestrated cuffs

Stéphan Haulon, *Lille, France*

17:58-18:00

Discussion

18:00-18:08

Chimney grafts

Giovanni Torsello, *Münster, Germany*

18:08-18:10

Discussion

18:10-18:18

Upward migration and type Ib endoleak years after EVAR – a word of caution

Hence Verhagen, *Rotterdam, Netherlands*

18:18-18:20

Discussion

18:20-18:30

Panel discussion

Additional Aortic activities

NEW CX Edited Live Cases – Aortic

Tuesday 28 April - [Click here](#)

CX Abstracts – Abdominal Aortic

Tuesday 28 April and Thursday 30 April - [Click here](#)

CX Abstracts – Thoracic Aortic

Wednesday 29 April - [Click here](#)

Thursday 30 April 2015 – Main Programme

CAROTID CONTROVERSIES

Chairman: Ross Naylor, *Leicester, United Kingdom*

Moderator: Frans Moll, *Utrecht, Netherlands*

08:00-08:09

Definition of 'best medical therapy' for carotid disease

Martin Brown, *London, United Kingdom*

08:09-08:11

Discussion

08:11-08:20

Resistance to platelet inhibitory therapy and stroke risk in patients with carotid disease

Charles McCollum, *Manchester, United Kingdom*

08:20-08:22

Discussion

08:22-08:32

Debate: Selective carotid screening is justified in modern clinical practice

For the motion: Peter Schneider, *Honolulu, United States*

Against the motion: Ankur Thapar, *Harlow, United Kingdom*

08:32-08:37

Discussion and vote

08:37-08:46

Carotid artery stenting in the hyperacute period after onset of symptoms: 'The rule of 5'

Gioachino Coppi, *Modena, Italy*

08:46-08:48

Discussion

08:48-08:57

Is there any role for intervention in acute carotid dissection?

Colin Derdeyn, *St Louis, United States*

08:57-08:59

Discussion

08:59-09:08

Results of urgent carotid intervention after thrombolysis following stroke

Martin Björck, *Uppsala, Sweden*

09:08-09:10

Discussion

09:10-09:19

An algorithm for predicting late stroke risk in asymptomatic patients

Andrew Nicolaides, *London, United Kingdom*

09:19-09:21

Discussion

09:21-09:30

The significance of symptomatic vertebral artery disease

Hugh Markus, *Cambridge, United Kingdom*

09:30-09:32

Discussion

09:32-09:42

Debate: Robotic navigation improves the results of carotid stenting

For the motion: Celia Riga, *London, United Kingdom*

Against the motion: Trevor Cleveland, *Sheffield, United Kingdom*

09:42-09:47

Discussion and vote

09:47-10:00

Panel discussion

COFFEE

THORACIC AORTIC CONTROVERSIES

Stroke during aortic arch interventions

Chairperson: Janet Powell, *Imperial College, London, United Kingdom*

Moderator: Frank Veith, *New York, United States*

10:30-10:37

The frequency of cerebral embolisation after aortic arch catheterisation

Richard Gibbs, *London, United Kingdom*

10:37-10:40

Discussion

10:40-10:47

The reporting of cerebral embolisation after aortic arch catheterisation

Regula von Allmen, *St Gallen, Switzerland*

10:47-10:50

Discussion

10:50-10:57

The value of medication such as statins before aortic arch catheterisation

Frank Lederle, *Minneapolis, United States*

10:57-11:00

Discussion

11:00-11:05

Panel discussion

11:05-11:15

Debate: Low profile endovascular aortic devices have more benefits than disadvantages

For the motion: Eric Verhoeven, *Nuremberg, Germany*

Against the motion: Peter Holt, *London, United Kingdom*

11:15-11:20

Discussion and vote

Interventions for ascending and arch of the aorta

Chairman: Roger Greenhalgh, *Imperial College, London, United Kingdom*

Moderator: Mait Thompson, *London, United Kingdom*

11:20-11:27

Micromesh use to reduce cerebral embolisation during carotid stenting

Alberto Cremonesi, *Cotignola, Italy*

11:27-11:30

Discussion

11:30-11:37

Ascending aortic reconstruction considerations

Rodney White, *Torrance, United States*

11:37-11:40

Discussion

11:40-11:47

TEVAR in the aortic arch – influence of the proximal landing zone on outcome

Dittmar Böckler, *Heidelberg, Germany*

11:47-11:50

Discussion

11:50-11:57

Branched stent grafts for the treatment of complex arch lesions

Piergiorgio Cao, *Rome, Italy*

11:57-12:00

Discussion

12:00-12:07

Open surgery

Stephen Large, *Cambridge, United Kingdom*

12:07-12:10

Discussion

12:10-12:18

Launch: Early clinical experience of a new thoracic branched device for the aortic arch

Michael Dake, *Stanford, United States*

12:18-12:21

Discussion

12:21-12:30

Panel discussion

LUNCH - Food will also be served in the Main Auditorium

Industry sponsored satellite

12:30-13:30 [Click here](#)

Interventions for ascending and arch of the aorta (continued)

Chairman: Andrew Holden, *Auckland, New Zealand*

Moderator: Colin Bicknell, *Imperial College, London, United Kingdom*

13:30-13:40

Debate: Hybrid beats total TEVAR wherever it can be used

For the motion: Franco Grego, *Padua, Italy*

Against the motion: Frans Moll, *Utrecht, Netherlands*

13:40-13:45

Discussion and vote

13:45-13:55

Debate: Endovascular branched graft beats open surgery for the left subclavian artery

For the motion: Jean Panneton, *Norfolk, United States*

Against the motion: Marcus Brooks, *Bristol, United Kingdom*

13:55-14:00

Discussion and vote

14:00-14:08

Complex arch and thoracic aortic procedures using robotic system

Thomas Nolte, *Bad Bevensen, Germany*

14:08-14:10

Discussion

14:10-14:20

Debate: The heyday of open aortic surgery is over

For the motion: Frank Veith, *New York, United States*

Against the motion: Hans-Henning Eckstein, *Munich, Germany*

14:20-14:25

Discussion and vote

14:25-14:35

Panel discussion on interventions for ascending and arch of the aorta

Controversies in chronic type B dissection of the aorta

14:35-14:44

Predictions of clinical success after TEVAR for chronic dissection

Matt Thompson, *London, United Kingdom*

14:44-14:46

Discussion

14:46-14:55

Factors that predict success after TEVAR for chronic type B dissection

Hervé Rousseau, *Toulouse, France*

14:55-14:57

Discussion

14:57-15:06

Technique of embolisation of false lumen

Tilo Kolbel, *Hamburg, Germany*

15:06-15:08

Discussion

15:08-15:17

Spinal cord protection – related complications in chronic type B dissection

Vincent Rimbau, *Barcelona, Spain*

15:17-15:19

Discussion

15:19-15:30

Panel discussion on type B dissection of the aorta

TEA - Refreshments will also be served in the Main Auditorium

Industry sponsored satellite

15:30-16:00 [Click here](#)

Current best practice in the management of chronic type B dissection

Chairman: Matt Thompson, *London, United Kingdom*

Moderator: Dittmar Bœckler, *Heidelberg, Germany*

16:00-16:10

Debate: Long-term results following intervention for sub-acute uncomplicated type B dissection warrant intervention

For the motion: Christoph Nienaber, *Rostock, Germany*

Against the motion: Ross Milner, *Chicago, United States*

16:10-16:15

Discussion and vote

16:15-16:23

Dissection algorithm

Michael Dake, *Stanford, United States*

16:23-16:25

Discussion

16:25-16:33

The impact of timing in the treatment of acute dissection

Nimesh Desai, *Philadelphia, United States*

16:33-16:35

Discussion

Descending thoracic aorta, thoracoabdominal and juxtarenal

16:35-16:43

MR elastography for optimal durability of thoracic endografts

Rachel Clough, *London, United Kingdom*

16:43-16:45

Discussion

16:45-16:53

Risk score for open repair, EVAR and thoracic interventions

Ian Loftus, *London, United Kingdom*

16:53-16:55

Discussion

16:55-17:05

Debate: The threshold diameter for intervention of the thoracic aorta is unknown

For the motion: Janet Powell, *Imperial College, London, United Kingdom*

Against the motion: Vincent Riambau, *Barcelona, Spain*

17:05-17:10

Discussion and vote

17:10-17:18

Two-stage TEVAR yields lower mortality and more protection against spinal cord injury

Matthew Eagleton, *Cleveland, United States*

17:18-17:20

Discussion

17:20-17:28

Renal revascularisation during open TAAA with Hybrid Vascular Graft

Roberto Chiesa, *Milan, Italy*

17:28-17:30

Discussion

17:30-17:38

Strategies to reduce paraplegia after TAAA repair (endovascular and open)

Theódosios Bisdas, *Münster, Germany*

17:38-17:40

Discussion

17:40-18:00

Panel discussion

Additional Aortic activities

NEW CX Edited Live Cases – Aortic

Tuesday 28 April - [Click here](#)

CX Abstracts – Abdominal Aortic

Tuesday 28 April and Thursday 30 April - [Click here](#)

CX Abstracts – Thoracic Aortic

Wednesday 29 April - [Click here](#)

Friday 1 May 2015 – Main Programme

VENOUS CONTROVERSIES

Superficial venous controversies

Chairman: Ian Franklin, *Imperial College, London, United Kingdom*

Moderator: Mark Whiteley, *Guildford, United Kingdom*

[Click here](#) to read about the highlights of the Venous Controversies 2015.

Truncal ablation

Thermal

Radiofrequency methods and their differences

08:00-08:07

Five-year data using a 7cm catheter system

Olivier Pichot, *Grenoble, France*

08:07-08:09

Discussion

08:09-08:16

Benefits of bipolar radiofrequency technology

Isaac Nyamekye, *Worcester, United Kingdom*

08:16-08:18

Discussion

08:18-08:25

The unipolar approach for radiofrequency

Attila Szabo, *Budapest, Hungary*

08:25-08:27

Discussion

Endovenous Laser Therapy

08:27-08:34

Laser fibre types – design and outcome

Ian Chetter, *Hull, United Kingdom*

08:34-08:36

Discussion

08:36-08:46

Panel discussion on thermal truncal ablation

Non-thermal

08:46-08:53

The mechanochemical method of ablation comes of age

Alun Davies, *Imperial College, London, United Kingdom*

08:53-08:55

Discussion

08:55-09:02

Endovenous glue ablation – Variclose

Kursat Bozkurt, *Istanbul, Turkey*

09:02-09:04

Discussion

09:04-09:11

The use of cyanoacrylate adhesive for the treatment of refluxing great saphenous vein – VenaSeal

Guido Lengfellner, *Regensburg, Germany*

09:11-09:13

Discussion

09:13-09:20

A comparison of thermal and non-thermal ablation

Tristan Lane, *London, United Kingdom*

09:20-09:22

Discussion

09:22-09:29

Optimal results of foam sclerotherapy

Attilio Cavezzi, *San Benedetto del Tronto, Italy*

09:29-09:31

Discussion

09:31-09:38

Foam phlebectomy techniques and outcomes

Michael Cumming, *St Louis Park, United States*

09:38-09:40

Discussion

09:40-09:50

Panel discussion on non-thermal truncal ablation

Perforating vein intervention

09:50-09:57

Identification of those that need correcting

Barrie Price, *Guildford, United Kingdom*

09:57-10:00

Discussion

COFFEE - Refreshments will also be served in the Main Auditorium

Venous thrombosis – incidence, consequence and towards a Patient Pathway

With an unrestricted educational grant from Boston Scientific

Chairman: Fabrizio Fanelli, *Rome, Italy*

10:00-10:03

Coffee & snacks

10:03-10:09

From venous thrombosis to post-thrombotic syndrome

Marzia Lugli, *Modena, Italy*

10:09-10:12

Discussion

10:12-10:18

Building an interventional pathway

Gerard O'Sullivan, *Galway, Ireland*

10:18-10:21

Discussion

10:21-10:28

Chairman's case discussion with audience interaction

Sclerotherapy and laser therapy of thread veins

Chairman: Ian Franklin, *Imperial College, London, United Kingdom*

Moderator: Stephen Black, *London, United Kingdom*

10:30-10:40

Debate: Duplex scanning is mandatory before treatment of asymptomatic cosmetic thread veins

For the motion: Mark Whiteley, *Guildford, United Kingdom*

Against the motion: Alun Davies, *Imperial College, London, United Kingdom*

10:40-10:45

Discussion and vote

10:45-10:52

Thread veins need compression

Philip Coleridge-Smith, *London, United Kingdom*

10:52-10:54

Discussion

Superficial and deep venous imaging

Chairman: Alun Davies, *Imperial College, London, United Kingdom*

Moderator: Ian Franklin, *Imperial College, London, United Kingdom*

10:54-11:01

The algorithm of choice of imaging modality, duplex, venography and IVUS and the place of CT and MR venography

Stephen Black, *London, United Kingdom*

11:01-11:03

Discussion

11:03-11:10

Improved clinical outcomes consequent upon excellent pelvic imaging

Mark Whiteley, *Guildford, United Kingdom*

11:10-11:12

Discussion

11:12-11:19

CT and MR venography and the limitations of venography in the lying position

Narayan Karunanithy, *London, United Kingdom*

11:19-11:21

Discussion

11:21-11:28

The measurement of a deep venous stenosis

Carsten Arnoldussen, *Maastricht, Netherlands*

11:28-11:30

Discussion

11:30-11:37

The range of use of state-of-the-art duplex scanning in experienced hands

Judith Holdstock, *Guildford, United Kingdom*

11:37-11:39

Discussion

11:39-12:05

Panel discussion on venous imaging

Venous interventions and pathways

12:05-12:12

The use of coils and foam into pelvic veins

Tony Lopez, *London, United Kingdom*

12:12-12:14

Discussion

12:14-12:21

Optimal care pathway for a leg ulcer patient

Manj Gohel, *Cambridge, United Kingdom*

12:21-12:23

Discussion

12:23-12:30

Panel discussion on venous interventions and pathways

LUNCH

Deep venous controversies

Deep venous stents

Chairman: Stephen Black, *London, United Kingdom*

Moderator: Frans Moll, *Utrecht, Netherlands*

13:30-13:37

The value of IVUS in planning and deployment of deep venous stents

Marzia Lugli, *Modena, Italy*

13:37-13:39

Discussion

13:39-13:46

The Zilver Vena stent

Gerard O'Sullivan, *Galway, Ireland*

13:46-13:48

Discussion

13:48-13:55

The VENITI stent

Olivier Hartung, *Marseille, France*

13:55-13:57

Discussion

13:57-14:04

The sinus-Venous stent

Rick de Graaf, *Maastricht, Netherlands*

14:04-14:06

Discussion

14:06-14:16

Panel discussion on deep venous stents

Catheter-directed thrombolysis and thrombectomy

14:16-14:23

Methods to estimate the age and nature of a deep venous occlusion

Prakash Saha, *London, United Kingdom*

14:23-14:25

Discussion

14:25-14:32

Evidence base is needed to change management of acute deep vein thrombosis

Ander Cohen, *London, United Kingdom*

14:32-14:34

Discussion

14:34-14:41

Acoustic energy thrombolytic technology for remote clot removal, including pulmonary embolism – Ekosonic

Julian Hague, *London, United Kingdom*

14:41-14:43

Discussion

14:43-14:50

Reconstruction of the inferior vena cava and Angiovac for inferior vena cava occlusion

Iris Baumgartner, *Bern, Switzerland*

14:50-14:52

Discussion

15:52-14:59

Detachment of occlusive thrombus in deep vein, aspiration, fragmentation and removal from veins or arteries –

Rotarex and Aspirex

Michael Lichtenberg, *Arnsberg, Germany*

14:59-15:01

Discussion

15:01-15:08

Breaking of thrombus and removal from peripheral veins and arteries – AngioJet

Gerard O'Sullivan, *Galway, Ireland*

15:08-15:10

Discussion

15:10-15:30

Panel discussion on catheter-directed thrombolysis and thrombectomy

Additional Venous activities

CX Abstracts – Venous

Tuesday 28 April - [Click here](#)

NEW CX Venous Workshop

Wednesday 29 April and Thursday 30 April - [Click here](#)

Tuesday | Wednesday | Thursday | Friday